Serum carnitine levels and levocarnitine supplementation in institutionalized Huntington's disease patients

Neurological Sciences

Volumn 34, Issue 1, 2013, Pages 93-98

  Cuturic, Miroslav ^a   Abramson, Ruth K ^a   Moran, Robert R ^b   Hardin, James W ^b   Frank, Elaine M ^b   Sellers, Andrea A ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Carnitine; Catabolism; Huntington's disease; Levocarnitine; Valproic acid

Indexed keywords

CARNITINE;

ABSENCE OF SIDE EFFECTS; ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BEHAVIOR; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; HUMAN; HUNTINGTON CHOREA; HYPOCARNITINEMIA; MALE; METABOLIC DISORDER; MONITORING; MOTOR PERFORMANCE; NURSING HOME; PREVALENCE; RETROSPECTIVE STUDY; SUPPLEMENTATION;

ADULT; ANTICONVULSANTS; CARNITINE; DATABASES, FACTUAL; DIET; DIETARY SUPPLEMENTS; FEMALE; HOSPITALIZATION; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NUTRITIONAL STATUS; RETROSPECTIVE STUDIES; VALPROIC ACID;

EID: 84872675239     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-012-0952-x     Document Type: Article

References (37)

1. Chen Q, Surmeier DJ, Reiner A (1999) NMDA and non-NMDA receptor-mediated excitotoxicity are potentiated in cultured striatal neurons by prior chronic depolarization. Exp Neurol 159:283-296
2. Perluigi M, Poon HF, Maragos W, Pierce WM, Klein JB, Calabrese V, Cini C, De Marco C, Butterfield DA (2005) Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease. Mol Cell Proteomics 4:1849-1861
3. Klepac N, Relja M, Klepac R, Hećimović S, Babić T, Trkulja V (2007) Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects: a cross-sectional study. J Neurol 254:1676-1683
4. Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, Sanchez-Pernaute R, de Yébenez JG, Boesiger P, Weindl A, Maguire RP (1996) Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 119(Pt 6):2085-2095
5. Martin LJ, Blackstone CD, Huganir RL, Price DL (1992) Cellular localization of a metabotropic glutamate receptor in rat brain. Neuron 9:259-270
6. Schilling G, Coonfield ML, Ross CA, Borchelt DR (2001) Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett 315:149-153
7. Rebouche CJ (2004) Kinetics, pharmacokinetics, and regulation of l-carnitine and acetyl-l-carnitine metabolism. Ann N Y Acad Sci 1033:30-41
8. Evans AM, Fornasini G (2003) Pharmacokinetics of l-carnitine. Clin Pharmacokinet 42:941-967
9. Malaguarnera M, Vacante M, Motta M, Malaguarnera M, Volti GL, Galvano F (2009) Effect of l-carnitine on the size of low-density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin. Metabolism 58:1618-1623
10. Malaguarnera M, Vacante M, Avitabile T, Malaguarnera M, Cammalleri L, Motta M (2009) l-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. Am J Clin Nutr 89:71-76
11. Galvano F, Volti GL, Malaguarnera M, Avitabile T, Antic T, Vacante M, Malaguarnera M (2006) Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert Opin Pharmacother 10:1875-1882
12. Rani PJA, Panneerselvam C (2001) Carnitine as a free radical scavenger in aging. Exp Gerontol 6:1713-1726
13. Koudelová J, Mourek J, Drahota Z, Rauchová H (1994) Protective effect of carnitine on lipoperoxide formation in rat brain. Physiol Res 43:387-389
14. Malaguarnera M, Cammalleri L, Gargante MP, Vacante M, Colonna V, Motta M (2007) l-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. Am J Clin Nutr 86:1738-1744
15. Malaguarnera M, Vacante M, Motta M, Giordano M, Malaguarnera G, Bella R, Nunnari G, Rampello L, Pennisi G (2011) Acetyl-l-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial. Metab Brain Dis 26:281-289
16. Malaguarnera M, Bella R, Vacante M, Giordano M, Malaguarnera G, Gargante MP, Motta M, Mistretta A, Rampello L, Pennisi G (2011) Acetyl-l-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol 46:750-759
17. Malaguarnera M, Pistone G, Astuto M, Vecchio I, Raffaele R, Lo Giudice E, Rampello L (2006) Effects of l-acetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial. Dig Dis Sci 51:2242-2247
18. Malaguarnera M, Pistone G, Elvira R, Leotta C, Scarpello L, Liborio R (2005) Effects of l-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 11:7197-7202
19. Mock CM, Schwetschenau KH (2012) Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy. Am J Health Syst Pharm 69:35-39
20. Vamos E, Voros K, Vecsei L, Klivenyi P (2010) Neuroprotective effects of l-carnitine in a transgenic animal model of Huntington's disease. Biomed Pharmacother 64:282-286
21. Folstein M, Folstein SE, McHugh PR (1975) "Mini-Mental State" a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198
22. Huntington Study Group (1996) Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 11:136-142
23. National Academy of Sciences (1996) Summary of WIC nutrition risk criteria: a scientific assessment. Committee on Scientific Evaluation of WIC Nutrition Risk Criteria Food and Nutrition Board, Institute of Medicine. J Am Diet Assoc 96:925-930
24. Cuturic M, Abramson RK, Moran RR, Hardin JW, Hall AV (2011) Clinical correlates of low serum carnitine levels in hospitalized psychiatric patients. World J Biol Psychiatry 12(1):73-79
25. Cuturic M, Abramson RK, Moran RR, Hardin JW (2010) Clinical outcomes and low-dose levocarnitine supplementation in psychiatric inpatients with documented hypocarnitinemia: a retrospective chart review. J Psychiatr Pract 16:5-14
26. Longo N, di San Amat, Filippo C, Pasquali M (2006) Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 142C:77-85
27. Proulx F, Lacroix J, Qureshi IA, Nadeau D, Gauthier M, Lambert M (1997) Acquired carnitine abnormalities in critically ill children. Eur J Pediatr 156:864-869
28. Wennberg A, Hyltander A, Sjöberg A, Arfvidsson B, Sandström R, Wickström I, Lundholm K (1992) Prevalence of carnitine depletion in critically ill patients with undernutrition. Metabolism 41:165-171
29. Coppola G, Epifanio G, Auricchio G, Federico RR, Resicato G, Pascotto A (2006) Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet. Brain Dev 28:358-365
30. Pratley RE, Salbe AD, Ravussin E, Caviness JN (2000) Higher sedentary energy expenditure in patients with Huntington's disease. Ann Neurol 47:64-70
31. Breningstall GN (1990) Carnitine deficiency syndromes. Pediatr Neurol 6:75-81
32. Lheureux PE, Penaloza A, Zahir S et al (2005) Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence? Crit Care 9:431-440
33. Pons R, De Vivo DC (1995) Primary and secondary carnitine deficiency syndromes. J Child Neurol 10(suppl. 2):8-24
34. Malaguarnera M, Gargante MP, Cristaldi E, Vacante M, Risino C, Cammalleri L, Pennisi G, Rampello L (2008) Acetyl-l-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci 53:3018-3025
35. Goety CG, Tanner CM, Cohen JA, Thelen JA, Carroll VS, Klawans HL, Fariello RG (1990) l-Acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. Mov Disord 5:263-265
36. Eder K, Felgner J, Becker K et al (2005) Free and total carnitine concentrations in pig plasma after oral ingestion of various l-carnitine compounds. Int J Vitam Nutr Res 75:3-9
37. -(2007) Carnitor (levocarnitine) prescribing information. Sigma-Tau Pharmaceuticals Inc, Gaithersburg